UroGen Pharma Ltd. (URGN)
NASDAQ: URGN
· Real-Time Price · USD
9.65
-0.22 (-2.23%)
At close: May 15, 2025, 2:30 PM
-2.23% (1D)
| Bid | 9.63 |
| Market Cap | 444.94M |
| Revenue (ttm) | 91.87M |
| Net Income (ttm) | -138.43M |
| EPS (ttm) | -2.96 |
| PE Ratio (ttm) | -3.26 |
| Forward PE | -16.32 |
| Analyst | Buy |
| Ask | 9.67 |
| Volume | 565,475 |
| Avg. Volume (20D) | 539,950 |
| Open | 9.76 |
| Previous Close | 9.87 |
| Day's Range | 9.56 - 9.85 |
| 52-Week Range | 8.94 - 20.70 |
| Beta | 0.67 |
About URGN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol URGN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for URGN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsEarnings Surprise
UroGen Pharma has released their quartely earnings
on May 12, 2025:
2 weeks ago
+14.08%
UroGen Pharma shares are trading higher after the ...
Unlock content with
Pro Subscription
4 months ago
+4.63%
UroGen Pharma shares are trading higher after the company reported its ENVISION trial results in the February issue of The Journal of Urology.
